Faculty profile

Laurie Ailles

Back to faculty

ProfessorDepartment of Medical BiophysicsUniversity of Toronto

Laurie Ailles

Professor

Department of Medical Biophysics

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Scholar ORCID

Supervision signals

Professors usually supervise graduate students in their department's programs.
26 publications in the last five years, latest in 2026.
Senior (last) author on 4 recent papers, a sign of leading a research group.
Principal investigator on 7 research grants (7 CIHR), most recently in 2023.
Supervisor on 1 trainee award (1 CIHR), most recently in 2011.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

464

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Education

BSc, Biology
MSc, Pathology
PhD, Genetics
Post-doctoral Fellowship
Post-doctoral Fellowship

Profiles and links

University Profile Personal Website Google Scholar iDORCID

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Cancer Cancer genetics Mechanisms of carcinogenesis

Latest papers

Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target
Cell Reports Medicine · 2026
Picosecond infrared laser mass spectrometry for 10-second identification of lymphoproliferative imposter tumours in patient-derived xenografts.
Scientific reports · 2026
SULF1 in Cancer Associated Fibroblasts Promotes Invasion in Head and Neck Cancer Cell Lines.
Cancer medicine · 2026

All 59 publications

Latest funding

The ASCC complex connects replication stress to the cGAS-STING-mediated innate immune response in clear cell renal cell carcinoma
CIHR · 2026 · Co-investigator
$952,426
Targeting PRMT1 in Clear Cell Renal Cell Carcinoma
CIHR · 2023 · Nominated PI
$776,475
Targeted and immuno-therapy to overcome innate and acquired resistance in aggressive MAPK-addicted cancers.
CIHR · 2022 · Co-investigator
$990,675

All 18 grants and awards

59 publications.

Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target

Govindarajan M, Mejia-Guerrero S, Chafe SC, Khan S, Shi W, Waas M, Rossotti MA, Khoo A, Liu LY, Ignatchenko V

Cell Reports Medicine20262 citations

DOI: 10.1016/j.xcrm.2025.102578

Picosecond infrared laser mass spectrometry for 10-second identification of lymphoproliferative imposter tumours in patient-derived xenografts.

Ye LA, Vlaminck D, Fiorante A, Dabija LG, Talbot F, Froment J, Azaizeh A, Hou L, Li M, Wang Y, Cao P, Shouk D, Shouk R, Tsao MS, Ailles L, O'Brien C, Lok BH, Pham NA, Zarrine-Afsar A

Scientific reports2026

DOI: 10.1038/s41598-025-33064-w PMID: 41501313

SULF1 in Cancer Associated Fibroblasts Promotes Invasion in Head and Neck Cancer Cell Lines.

Mukherjee P, Benicky J, Panigrahi A, Ailles L, Goldman R

Cancer medicine2026

DOI: 10.1002/cam4.71540 PMID: 41549062

Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer.

Zeng PYF, Meens J, Karimi AH, Pan H, Cecchini MJ, Jarycki L, Ryan SB, Dawson AE, Shaikh MH, Palma DA, Winquist E, Gunaratnam L, Mymryk JS, Barrett JW, Boutros PC, Ailles L, Nichols AC

Cell reports. Medicine2026

DOI: 10.1016/j.xcrm.2026.102820 PMID: 42143022

MicroRNA-mediated PTEN downregulation as a novel non-genetic mechanism of acquired resistance to PI3Kα inhibitors of head & neck squamous cell carcinoma

Pulito C, Vaccarella S, Palcau AC, Ganci F, Brandi R, Frascolla C, Sacconi A, Canu V, Benedetti A, De Pascale V

Drug Resistance Updates20254 citations

DOI: 10.1016/j.drup.2025.101251

In vitro and in vivo derived macrophages occupy distinct phenotypic states.

Chevrier S, Zanotelli VRT, Schulz D, Robinson MD, Ailles L, Jewett MAS, Gedye C, Reis B, Bodenmiller B

bioRxiv : the preprint server for biology2025

DOI: 10.1101/2025.09.20.677495 PMID: 41000873

PRMT1 inhibitor MS023 suppresses RNA splicing to sensitize small cell lung cancer to DNA damaging agents.

Aparnathi MK, Ul Haq S, St-Germain J, Nixon KCJ, Walton J, Song L, Majeed S, Patel PS, Subramaniam R, Philip V, Marcellus R, Barsyte-Lovejoy D, Al-Awar R, Hakem R, Arrowsmith CH, Ailles L, Raught B, Lok BH

Neoplasia (New York, N.Y.)2025

DOI: 10.1016/j.neo.2025.101176 PMID: 40413955

VHL Gene Restoration Supports RCC Reprogramming to iPSCs but Does Not Ensure Line Stability.

Lichner Z, Shamshirgaran Y, Pieczonka K, Jonebring A, Kibschull M, Shynlova O, Meens J, Kim RH, Ailles L, Bilican B, Hicks R, Rogers IM

Cancers2025

DOI: 10.3390/cancers17223693 PMID: 41301058

Comparative single-cell transcriptomic profiling of patient-derived renal carcinoma cells in cellular and animal models of kidney cancer.

Huang R, Kee L, Gont A, Meens J, Ferens FG, Irwin MS, Ailles L, Yuzwa SA, Robinson CM, Ohh M

FEBS open bio2025

DOI: 10.1002/2211-5463.70022 PMID: 40241258

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality.

Cunningham CE, Vizeacoumar FS, Zhang Y, Kyrylenko L, Both S, Maranda V, Dong H, Price JDW, Gao P, Wagner K, Wu Y, Lazell-Wright M, Ganapathysamy A, Hari R, Bhanumathy KK, Denomy C, Saxena A, Vizeacoumar JP, Morales AM, Khan F, Mosley S, Chen A, Katrii T, Zoller BGE, Rajamanickam K, Walke P, Gong L, Patel H, Elhasasna H, Dahiya R, Abuhussein O, Dmitriev A, Freywald T, Munhoz EP, Ruppin E, Lee JS, Rox K, Koebel M, Hopkins L, Lee CH, Yadav S, Gasparoni G, Walter J, Krishnan A, Datla R, Toosi B, Baker K, Meens J, Cescon DW, Ailles L, Leary SC, Wu Y, Empting M, Kiemer AK, Freywald A, Vizeacoumar FJ

Cell genomics2025

DOI: 10.1016/j.xgen.2025.100876 PMID: 40347943

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Laurie Ailles

Research

Latest papers

Latest funding

Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target

Picosecond infrared laser mass spectrometry for 10-second identification of lymphoproliferative imposter tumours in patient-derived xenografts.

SULF1 in Cancer Associated Fibroblasts Promotes Invasion in Head and Neck Cancer Cell Lines.

Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer.

MicroRNA-mediated PTEN downregulation as a novel non-genetic mechanism of acquired resistance to PI3Kα inhibitors of head & neck squamous cell carcinoma

In vitro and in vivo derived macrophages occupy distinct phenotypic states.

PRMT1 inhibitor MS023 suppresses RNA splicing to sensitize small cell lung cancer to DNA damaging agents.

VHL Gene Restoration Supports RCC Reprogramming to iPSCs but Does Not Ensure Line Stability.

Comparative single-cell transcriptomic profiling of patient-derived renal carcinoma cells in cellular and animal models of kidney cancer.

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality.

Frequent collaborators

Thomas Kislinger

Wei Xu

Fei-Fei Liu

Arash Zarrine-Afsar

Antonio Finelli

Jason Moffat

Eric Winquist

Michael Ohh

Brian Raught

Alison McGuigan

Rama Khokha

Ming-Sound Tsao

Jacek Majewski

Robert Rottapel

Anne-Marie Mes-Masson

Oksana Shynlova

Lakshman Gunaratnam

Kristi Baker

Anna Spreafico

Frank Wuest

Scott Bratman

Neil Fleshner

David Cescon

Giovanni Blandino

Girish Kulkarni

Sheila Singh

Afsaneh Lavasanifar

Nada Jabado

Geoffrey Liu

Hong Han

Paola Muti